Patient characteristics and results of patients with PMF receiving allogenic SCT (data at the time of transplant) or nonexperimental conventional therapy (data at the time of diagnosis)
| . | Allogenic SCT . | Conventional therapy . | ||||
|---|---|---|---|---|---|---|
| Patients (n) | 188 | 255 | ||||
| Median age at diagnosis, y (range) | 50 (20-65) | 55 (18-65) | ||||
| DIPSS, n | At transplant | At diagnosis* | ||||
| Low risk | 22 | 125 | ||||
| Int-1 | 38 | 75 | ||||
| Int-2 | 84 | 52 | ||||
| High risk | 44 | 3 | ||||
| Gender, n | ||||||
| Male | 108 | 154 | ||||
| Female | 80 | 101 | ||||
| Time from diagnosis to transplant, y (range) | 1.2 (0.0-22.2) | |||||
| Conditioning regimen, n | ||||||
| RIC | 91 | |||||
| MAC | 97 | |||||
| Donor, n | ||||||
| Matched unrelated or mismatch related | 102 | |||||
| Matched related | 86 | |||||
| Survival proportion† | Year | Year | ||||
| 1 | 5 | 10 | 1 | 5 | 10 | |
| Low risk | 100 | 69 (48-99) | 60 (38-95) | 98 (96-100) | 95 (90-99) | 92 (86-99) |
| Int-1 | 78 (55-100) | 52 (33-83) | 41 (24-70) | 97 (93-100) | 77 (67-89) | 63 (51-77) |
| Int-2 | 82 (68-98) | 50 (37-67) | 32 (21-48) | 77 (67-88) | 41 (32-54) | 11 (5-22) |
| High risk | 65 (46-92) | 32 (19-56) | 27 (15-49) | 67 (30-100) | 11 (3-44) | 1 (0-10) |
| . | Allogenic SCT . | Conventional therapy . | ||||
|---|---|---|---|---|---|---|
| Patients (n) | 188 | 255 | ||||
| Median age at diagnosis, y (range) | 50 (20-65) | 55 (18-65) | ||||
| DIPSS, n | At transplant | At diagnosis* | ||||
| Low risk | 22 | 125 | ||||
| Int-1 | 38 | 75 | ||||
| Int-2 | 84 | 52 | ||||
| High risk | 44 | 3 | ||||
| Gender, n | ||||||
| Male | 108 | 154 | ||||
| Female | 80 | 101 | ||||
| Time from diagnosis to transplant, y (range) | 1.2 (0.0-22.2) | |||||
| Conditioning regimen, n | ||||||
| RIC | 91 | |||||
| MAC | 97 | |||||
| Donor, n | ||||||
| Matched unrelated or mismatch related | 102 | |||||
| Matched related | 86 | |||||
| Survival proportion† | Year | Year | ||||
| 1 | 5 | 10 | 1 | 5 | 10 | |
| Low risk | 100 | 69 (48-99) | 60 (38-95) | 98 (96-100) | 95 (90-99) | 92 (86-99) |
| Int-1 | 78 (55-100) | 52 (33-83) | 41 (24-70) | 97 (93-100) | 77 (67-89) | 63 (51-77) |
| Int-2 | 82 (68-98) | 50 (37-67) | 32 (21-48) | 77 (67-88) | 41 (32-54) | 11 (5-22) |
| High risk | 65 (46-92) | 32 (19-56) | 27 (15-49) | 67 (30-100) | 11 (3-44) | 1 (0-10) |